MONTE ROSA THERAPEUTICS INC

GLUE30 Nov 2024
Healthcare
$9.23
+0.14 (+13.72%)
Lowest Today
$9.23
Highest Today
$10.44
Today’s Open
$9.23
Prev. Close
$9.11
52 Week High
$12.4
52 Week Low
$2.95
To Invest in MONTE ROSA THERAPEUTICS INC

MONTE ROSA THERAPEUTICS INC

Healthcare
GLUE30 Nov 2024
+0.14 (+13.72%)
1M
3M
6M
1Y
5Y
Low
$9.23
Day’s Range
High
$10.44
9.23
52 Week Low
$2.95
52-Week Range
52 Week High
$12.4
2.95
1 Day
-
1 Week
+22.31%
1 month return
+12.73%
3 month return
+70.95%
6 month return
+150.84%
1 Year return
+234.19%
3 Years return
-47.43%
5 Years return
-
10 Years return
-
Institutional Holdings
NEA Management Company, LLC
12.53
T. Rowe Price Associates, Inc.
9.74
venBio Select Advisor LLC
9.43
FMR Inc
8.31
Baker Bros Advisors LP
8.01
T. Rowe Price New Horizons
5.55
US Small-Cap Growth II Equity Comp
5.55

Market Status

Fundamentals
Market Cap
559.69 mln
PB Ratio
2.72
PE Ratio
0
Enterprise Value
361.2 mln
Total Assets
303.76 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Organisation
MONTE ROSA THERAPEUTICS INC
Employees
133
Industry
Biotechnology
CEO
Dr. Markus  Warmuth M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities